Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Abstract
Purpose Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Methods Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Results Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Conclusion Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are DDI and DGI studies demonstrating SVA influx to hepatocytes via the membrane transporter OATP1B1.
“Additionally, there are DDI and drug–gene interaction (DGI) studies demonstrating SVA influx to hepatocytes via the membrane transporter OATP1B1. 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [29]
The final PBPK models predicted the OATP1B1 DGI ratios within twofold of the observed for poor or intermediate function.
“The final PBPK models predicted the DGI ratios within twofold of the observed for poor or intermediate function 29 , 33 .”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [29]
The final PBPK models predicted the BCRP DGI ratios within twofold of the observed for poor or intermediate function.
“The final PBPK models predicted the DGI ratios within twofold of the observed for poor or intermediate function 29 , 36 .”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [29]
Several DGI studies describe an association between SVL disposition and BCRP transporter polymorphisms, but findings are inconsistent and the clinical importance is still highly debatable.
“Although several DGI studies describe an association between SVL disposition and BCRP transporter polymorphisms, 29 , 30 , 34 , 36 findings are inconsistent and the clinical importance is still highly debatable.”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [29]
There is limited availability of pharmacogenetic information, with only a few studies comprising a small number of subjects (4 to 15 individuals) for each transporter genotype.
“However, there is limited availability of pharmacogenetic information, with only a few studies comprising a small number of subjects (4 to 15 individuals) for each transporter genotype. 29 , 36”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [29]
Cites
Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Prieto Garcia, L., Lundahl, A., Ahlström, C., Vildhede, A., Lennernäs, H., & Sjögren, E. (2022) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12837 · Cited by 21 · see citing works
- Authors
- Birmingham, B. K., Bujac, S. R., Elsby, R., Azumaya, C. T., Wei, C., Chen, Y., Mosqueda-Garcia, R., & Ambrose, H. J.
- Affiliations
- AstraZeneca (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Birmingham, Bruce K.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2015-02-12
- Volume
- 71
- Issue
- 3
- Pages
- 341-355
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2469492348
- Cited by
- 153
- References
- 1
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 15 · 2023: 7 · 2022: 18 · 2021: 14 · 2020: 14 · 2019: 16 · 2018: 12 · 2017: 15 · 2016: 14 · 2015: 5
- FWCI
- 18.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- rosuvastatin, atorvastatin, simvastatin, simvastatin acid, statins, pharmacokinetics, Asian populations, drug transporters, AUC, maximum concentration, class effect
- MeSH terms
- Rosuvastatin Calcium, Atorvastatin, ATP Binding Cassette Transporter, Subfamily G, Member 2, Adolescent, Adult, Aged, Female, Genotype, Humans, Male, Middle Aged, Neoplasm Proteins, ATP-Binding Cassette Transporters, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Polymorphism, Single Nucleotide, Organic Anion Transporters, Liver-Specific Organic Anion Transporter 1, White People, Asian People, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review